

To,

31.03.2021

The Manager-Listing
NSE Limited
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding in BAL PHARMA LIMITED, Bangalore, as on F.Y ending 31st March, 2021.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



SHAILESH SIROYA

Copy to:

Compliance Officer

BAL PHARMA LIMITED

5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) BSE Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	SHAILESH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share / voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	19,95,459	13.46%	12.81%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	19,95,459	13.46%	12.81%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2021


SHAILESH SIROYA

To,
The BSE Limited
Mumbai.

31.03.2021

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations, 2011.

With reference to the above, I would like to confirm that I have not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2021.

Please take this intimation on record.

Thanking You.



Shailesh Siroya

C.C to The Chairman, Audit Committee